Bal Pharma clarifies XBRL filing variations, FY26 results unchanged
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE noticed variations between XBRL filing and PDF financial results for Q4 FY26 in standalone PAT, EPS, and cash flow figures. The company clarified these were technical issues in the XBRL filing utility, refiled XBRL to match the approved PDF, and confirmed no change in Board-approved results. Auditors gave unmodified opinion. FY26 standalone revenue Rs 31,079.70 lakhs, PAT Rs 675.12 lakhs (down from Rs 779.95 lakhs), EPS Rs 4.51. Dividend of Re 1.20 per share (12 percent) recommended.
No material impact. Routine XBRL reconciliation resolved. Results, dividend and clean audit opinion stand. Promoters to receive 10 lakh warrants via preferential issue.